From Wikipedia, the free encyclopedia
Monoclonal antibody
Vobarilizumab (
INN ; development code ALX0061 ) is a humanized bispecific
nanobody (Llama-derived heavy-chain only (Vhh) antibody) designed for the treatment of inflammatory autoimmune diseases.
[1]
[2]
[3]
This drug was developed by
Ablynx NV to block
interleukin-6 receptor . Vobarilizumab has been evaluated in patients with
rheumatoid arthritis
[4] as well as in
lupus .
[5]
References
^
Statement On A Nonproprietary Name Adopted By The USAN Council - Vobarilizumab ,
American Medical Association .
^
World Health Organization (2015).
"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 114" (PDF) . WHO Drug Information . 29 (4).
^ Hassan N, Choy E (September 2020).
"Interleukin-6 inhibitors" . In Scott DL, Galloway J, Cope A, Pratt A, Strand V (eds.). Oxford Textbook of Rheumatoid Arthritis . Oxford University Press. p. 394.
doi :
10.1093/med/9780198831433.003.0032 .
ISBN
978-0-19-256710-9 .
^
"A Phase II Multicenter, Open-Label Extension Study Assessing the Long-Term Efficacy and Safety of Subcutaneous ALX-0061 in Subjects with Moderate to Severe Rheumatoid Arthritis Who Have Completed One of the Preceding Phase IIb Studies with ALX-0061" . 19 July 2019.
^
"A Phase II Multicenter, Randomized, Double-blind, Placebo Controlled, Dose-range Finding Study to Evaluate the Safety and Efficacy of ALX-0061 Administered Subcutaneously in Subjects with Moderate to Severe Active Systemic Lupus Erythematosus" . 12 February 2019.